Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.43 |
| ▸ | CCR9 | P51686 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4307899 | 0.85 | GRM2 (0.46) | CCR9GRM2MAPTNPSR1SMN1; SMN2 | |
| SCHEMBL4316829 | 0.82 | PDE5A (0.45) | PDE5AGRM2MAPTNPSR1SMN1; SMN2 | |
| SCHEMBL4308972 | 0.82 | CCR9 (0.41) | CCR9MAPTMTNR1AMTNR1B | |
| SCHEMBL4314718 | 0.81 | CCR9 (0.42) | CCR9MAPTMTNR1AMTNR1B | |
| SCHEMBL13924694 | 0.80 | CCR9 (0.44) | CCR9GRM2MAPTNPSR1SMN1; SMN2 | |
| SCHEMBL4310962 | 0.79 | MAPT (0.40) | CCR9MAPTRXFP1MTNR1AMTNR1B | |
| SCHEMBL4308707 | 0.79 | CCR9 (0.54) | CCR9MAPT | |
| SCHEMBL4323857 | 0.79 | MAPT (0.39) | CCR9MAPTMTNR1AMTNR1B | |
| SCHEMBL4307331 | 0.79 | CCR9 (0.39) | CCR9MAPT | |
| SCHEMBL4310989 | 0.79 | PDE5A (0.48) | PDE5AGRM2MTNR1AMTNR1BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNN3, KCNN1, KCNN2 | PDE5A 142/4885CCR9 4698/4885GRM2 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.